ClinicalTrials.gg
CompletedNCT01161082Updated Jan 27, 2015

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

A Phase 1 interventional study of REGN727(SAR236553) in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-01-27.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
28th of 43
72 · median 107
Started
2010
the only one that year
Phase 1
9 of 43
none open now
Registered
1st of 43
by date
Lead sponsor
11 of 43
Regeneron Pharmaceuticals

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 28th largest by enrollment, is the only one that started in 2010, is one of 9 in phase 1, and was the 1st registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study will test the safety, tolerability, and bioeffects (how the body reacts to the drug) of REGN727 compared with placebo (an inactive substance that contains no medicine) in hyperlipidemic patients with or without atorvastatin therapy. The study drug and placebo will be administered by subcutaneous injection at the clinic. There will be a total of 2 or 3 study drug injections over 16 clinic visits, which will include 3 overnight stays(study duration 148 days, not including the screening period). Patients on atorvastatin will take their daily dose in the morning for the duration of the study. Patients will be monitored by the study staff for side effects and the body's response to the study drug. Vital signs(blood pressure, temperature, breathing and heart rate) will be checked, and blood and urine samples will be collected at some or all visits.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women with elevated cholesterol on stable doses of atorvastatin 10-40mg/day regimen
  • between 18.0 and 35.0 kg/m2, inclusive
  • For women of , a negative serum pregnancy test at the screening visit and a negative urine pregnancy test on day -2 or day -1
  • For men and women of childbearing potential, willingness to utilize adequate and not become pregnant (or have their partner[s] become pregnant)during the full duration of the study
  • Willing, committed and able to return for all the clinic visits and complete all study-related procedures
  • Able to read, and able to sign the form

Exclusion criteria

Exclusion Criteria:

  • History of MI, ACS, Angina, Stroke, peripheral vascular disease, or cardiac revascularization
  • Pregnant or breast-feeding women
  • Blood donation of any volume within 1 month prior to administration of study drug
  • Congestive heart failure
  • Consumption of greater than 1 quart of grapefruit juice per day
  • Previous exposure to any therapeutic or biological agent within 30 days of screening
  • History of alcohol or drug abuse within one year to the screening visit

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Group 1 with atorvastatin

    Dose 1 versus placebo

    Drug: REGN727(SAR236553)

  • Experimental
    Group 2 with atorvastatin

    Dose 1 versus placebo

    Drug: REGN727(SAR236553)

  • Experimental
    Group 3 with atorvastatin

    Dose 2 versus placebo

    Drug: REGN727(SAR236553)

  • Experimental
    Group 4 with atorvastatin

    Dose 2 versus placebo

    Drug: REGN727(SAR236553)

  • Experimental
    Group 5 with atorvastatin

    Dose 3 versus placebo

    Drug: REGN727(SAR236553)

  • Experimental
    Group 6 with atorvastatin

    Dose 3 versus placebo

    Drug: REGN727(SAR236553)

  • Experimental
    Group 7 without atorvastatin

    Dose 3 versus placebo

    Drug: REGN727(SAR236553)

  • Experimental
    Group 8 with atorvastatin

    Dose4 versus placebo

    Drug: REGN727(SAR236553)

Interventions

06

What researchers measure

Primary outcomes

  1. The primary endpoint in the study is to assess the incidence and severity of treatment-emergent adverse events in hyperlipidemic patients treated with REGN727 or placebo receiving stable doses of atorvastatin.

    Time frame: visit 4 (day 1) to visit 16 (day 148)

Secondary outcomes

  1. To assess the pharmacodynamic effect of REGN727 added to atorvastatin on lipids

    Time frame: Visit 4 (Day 1) to Visit 16 (Day 148)

  2. To assess the pharmacodynamic effect of monotherapy REGN727 in hyperlipidemic patients

    Time frame: Visit 4 (Day 1) to Visit 16 (Day 148)

  3. To assess the pharmacokinetics of REGN727 in hyperlipidemic patients with or without atorvastatin

    Time frame: Visit 4 (Day 1) to Visit 16 (Day 148)

07

Study locations

2 sites
  • Site 1
    Cincinnati, Ohio, United States
  • Site 2
    Knoxville, Tennessee, United States
08

References and documents

Publications

  • Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012 Mar 22;366(12):1108-18. doi: 10.1056/NEJMoa1105803. PubMed 22435370 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2010
First posted
Jul 13, 2010
Start
Jun 2010
Primary completionActual
May 2011
CompletionActual
May 2011
Last update
Jan 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01161082
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jul 13, 2010
Start date
Jun 2010
Primary completion
May 2011
Completion
May 2011
Last update
Jan 27, 2015

Study contacts

Gary Swergold, MD, PhD
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion